Lixisenatide
AVE0010, ZP10, des-38-proline-exendin-4(1-39)-Lys6-NH2
Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4 by deleting one proline and appending six lysine residues at the C-terminus. Unlike long-acting agonists it acts predominantly on postprandial glucose through sustained delay of gastric emptying. It is licensed for type 2 diabetes, though the standalone product has been withdrawn from several major markets on commercial grounds.
Mechanism
Lixisenatide is built on the exendin-4 scaffold: proline 38 is deleted and six lysines are added at the carboxy terminus, producing a 44-residue amidated peptide. Like exendin-4 it carries glycine at position 2 and is therefore resistant to DPP-4. The polylysine tail increases receptor affinity, and lixisenatide binds the GLP-1 receptor with roughly four-fold greater affinity than native GLP-1.
The pharmacologically interesting feature is duration rather than potency. With a half-life of about three hours, once-daily lixisenatide gives a pulse of receptor activation rather than continuous occupancy. Continuous GLP-1 receptor stimulation causes tachyphylaxis of the gastric-emptying effect through vagal adaptation, so long-acting agonists lose their braking effect on the stomach within weeks. Intermittent exposure does not, and lixisenatide therefore maintains a substantial delay in gastric emptying indefinitely. Clinically this translates into a compound that lowers postprandial glucose excursions markedly, particularly after the meal following injection, while doing comparatively little to fasting glucose. That profile made it a natural partner for basal insulin, and it is co-formulated with insulin glargine in a fixed-ratio product for exactly this reason.
What the research shows
GetGoal-Mono established monotherapy efficacy: over 12 weeks in 361 drug-naive adults, HbA1c fell by up to 0.85 percentage points against 0.19 with placebo, a placebo-adjusted reduction of 0.54 to 0.66 percentage points depending on the titration regimen. Roughly 50% of lixisenatide recipients reached HbA1c below 7.0% against 27% on placebo, and postprandial glucose excursion fell by about 75%. Nausea affected 23% versus 4.1% on placebo. The more clinically relevant work was in combination with basal insulin. GetGoal-L randomised 495 people already on basal insulin; HbA1c fell 0.74 percentage points versus 0.38 with placebo, a placebo-corrected difference of about 0.4 points, with postprandial glucose falling 3.8 mmol/L and weight 1.3 kg. Across the programme, HbA1c reductions were generally smaller than those achieved by long-acting agonists, but the postprandial glucose effect was consistently larger.
ELIXA provides the key safety and outcome data and is an important null result. It randomised 6,068 people with type 2 diabetes and a recent acute coronary syndrome and followed them for a median of 25 months. The primary composite of cardiovascular death, myocardial infarction, stroke or hospitalisation for unstable angina occurred with a hazard ratio of 1.02 (95% CI 0.89-1.17). Lixisenatide neither increased nor reduced cardiovascular risk, and there was no excess of pancreatitis or pancreatic cancer. It was the first GLP-1 receptor agonist cardiovascular outcomes trial to report, and its neutrality showed early that cardiovascular benefit is not a uniform class effect.
Evidence assessment
High-quality evidence
Lixisenatide holds regulator-approved labelling and is supported by the GetGoal phase 3 programme of more than ten randomised controlled trials, plus ELIXA, a 6,068-participant cardiovascular outcomes trial. The efficacy evidence is robust; the cardiovascular result was neutral, which is a finding rather than a weakness of the evidence base. All three cited studies were individually verified.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Preclinical only
Placebo-adjusted HbA1c reduction of 0.54 to 0.66 percentage points (within-group fall of up to 0.85 versus 0.19 on placebo). About 50% reached HbA1c below 7.0% versus 27% on placebo, with roughly 75% reduction in postprandial glucose excursion. Nausea affected 23% versus 4.1%.
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) Preclinical only
Placebo-corrected HbA1c reduction of about 0.4 percentage points (within-group 0.74 versus 0.38). HbA1c below 7.0% was reached by 28% versus 12%; postprandial glucose fell 3.8 mmol/L and weight 1.3 kg. Symptomatic hypoglycaemia occurred in 28% versus 22%.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Preclinical only
The primary composite cardiovascular endpoint occurred with a hazard ratio of 1.02 (95% CI 0.89-1.17). No increase in pancreatitis, pancreatic cancer or heart failure hospitalisation was seen.
Safety
Nausea is the commonest adverse effect and is more prominent than with some long-acting agonists because of the sustained gastric-emptying delay; vomiting and diarrhoea follow. Hypoglycaemia is uncommon with lixisenatide alone but frequent in combination with a sulfonylurea or insulin; in GetGoal-L symptomatic hypoglycaemia occurred in 28% on lixisenatide versus 22% on placebo, and dose reduction of the sulfonylurea is generally required. Because the peptide is cleared by glomerular filtration, exposure rises in renal impairment; use is not recommended at eGFR below 15 and requires caution below 30. Acute pancreatitis has been reported. Anti-drug antibodies develop in a majority of treated patients, as with other exendin-based peptides, and very high titres can reduce glycaemic response. Injection-site reactions and headache are common. Delayed gastric emptying can slow absorption of orally administered drugs with a narrow therapeutic index.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Authorised across the European Union from February 2013 and subsequently reflected in Great Britain marketing authorisations regulated by the MHRA. Availability of the standalone product has been reduced in a number of European markets on commercial grounds, while the fixed-ratio insulin glargine and lixisenatide combination has continued to be supplied. Readers should check current availability locally, as the position has changed repeatedly. Prescription-only medicine; not a controlled drug. |
| United States | Approved by the FDA in July 2016 as an adjunct to diet and exercise for glycaemic control in adults with type 2 diabetes, and separately as part of a fixed-ratio combination with insulin glargine. The standalone lixisenatide product was withdrawn from the US market in early 2023 for commercial reasons, with the manufacturer stating that the decision was unrelated to safety or efficacy. The fixed-ratio combination with insulin glargine has remained available. Prescription-only. |
| WADA (sport) | Not prohibited. Lixisenatide is not listed on the WADA Prohibited List and GLP-1 receptor agonists are not banned as a class. WADA's separate Monitoring Programme is revised annually and carries no sanctions; its current contents should be checked against the list in force for the relevant year. |
Questions
Its three-hour half-life means receptor stimulation is intermittent rather than continuous. That preserves the delay in gastric emptying, which fades with long-acting agonists, so lixisenatide chiefly lowers post-meal glucose spikes while having a comparatively small effect on fasting glucose and body weight.
The two are pharmacologically complementary. Basal insulin controls fasting glucose but does nothing for post-meal excursions; lixisenatide does the reverse. A fixed-ratio co-formulation exploits this, and trials of the combination showed better glycaemic control with less weight gain than intensifying insulin alone.
No. ELIXA, in 6,068 people after acute coronary syndrome, found a hazard ratio of 1.02 for the primary composite endpoint. It established cardiovascular safety but showed no benefit, in contrast to liraglutide, semaglutide and dulaglutide.
Availability has narrowed considerably. The standalone product was withdrawn in the United States in 2023 and has been discontinued in several other markets for commercial reasons, though the fixed-ratio combination with insulin glargine has generally remained on sale. Current availability should be checked locally.